Alnylam Pharmaceuticals

Yahoo Finance • 9 days ago

JPMorgan sees biotech sector at inflection point, resumes coverage on 14 Firms

Investing.com -- JPMorgan has reinstated ratings and price targets on 14 large-cap biotechnology companies, describing the sector as being at a critical “inflection point” as pipeline successes increasingly translate into profitable commer... Full story

Yahoo Finance • 11 days ago

StubHub, Jazz Pharmaceuticals upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Guggenheim upgraded StubHub (STUB) to... Full story

Yahoo Finance • 11 days ago

Alnylam Issues 2025 Corporate Responsibility Report

– Published Scope 1 and Scope 2 Greenhouse Gas (GHG) Emissions Reduction Framework through 2030 – – Expanded Global Patient Access and Support – CAMBRIDGE, Mass., May 19, 2026--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY... Full story

Yahoo Finance • 11 days ago

Here Are Tuesday’s Top Wall Street Analyst Research Calls: American Tower, Citigroup, CrowdStrike, Fortinet, Hanover Insurance, Jazz Pharmaceuticals, Stubhub, X-Energy, and More

Quick Read: The trading week started mixed as many of the same issues we saw last Friday remained front and center on Monday. There is a rumbling in the bond market that new Federal Reserve Chairman Kevin Warsh may have to raise rates thi... Full story

Yahoo Finance • 11 days ago

How Investors Are Reacting To Alnylam Pharmaceuticals (ALNY) New HELIOS-B Vutrisiran Data And Real-World Study

Earlier in May 2026, Alnylam Pharmaceuticals reported new HELIOS-B Phase 3 analyses showing its TTR silencer vutrisiran delivered durable transthyretin knockdown, consistent clinical benefit across high‑risk ATTR-CM subgroups, and low, pla... Full story

Yahoo Finance • 22 days ago

ClearBridge Large Cap Growth adds, and exits multiple positions in Q1

* ClearBridge’s Large Cap Growth ESG Strategy outperformed its Russell 1000 Growth Index benchmark in Q1 2026, as the broader market sell-off driven by Middle East tensions pushed the S&P 500 down 4.3% and the Russell 1000 Growth Index l... Full story

Yahoo Finance • 23 days ago

MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award

MBX Biosciences, Inc. CARMEL, Ind. and BURLINGTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of nove... Full story

Yahoo Finance • 29 days ago

Discover 3 Stocks That Might Be Trading Below Estimated Value

In the last week, the United States market has stayed flat, although it is up 29% over the past year with earnings forecasted to grow by 16% annually. In such a climate, identifying stocks that might be trading below their estimated value... Full story

Yahoo Finance • 29 days ago

Alnylam Pharmaceuticals Q1 Earnings Call Highlights

Alnylam Pharmaceuticals logo Key Points Alnylam reported a strong Q1 with $1.036 billion in combined net product revenues (up 121% YoY), led by the TTR franchise which generated $910 million (up 153% YoY) and benefited from increasing U.... Full story

Yahoo Finance • last month

Alnylam Pharmaceuticals (ALNY) Advances Diabetes Drug Into Phase 2 Trial

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 10 New Contenders for S&P 500 Index.Alnylam Pharmaceuticals (ALNY) Advances Diabetes Drug Into Phase 2 Trial On April 17, 2026, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) provided... Full story

Yahoo Finance • last month

Truist Lowers PT on Alnylam Pharmaceuticals (ALNY) to $505 From $515

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is one of the most oversold healthcare stocks to invest in. Truist cut the price target on Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) to $505 from $515 on April 13, reiterating a Buy rating on the... Full story

Yahoo Finance • 2 months ago

Oligonucleotides Market Research and Competitive Landscape Report 2026 Featuring Novartis, Astellas, Alnylam Pharmaceuticals, Ionis Pharmaceuticals

Company Logo Key opportunities in the oligonucleotide market include advancing therapeutics for rare and diverse diseases like neurodegenerative disorders and cancer, improving drug delivery systems, leveraging regulatory designations, an... Full story

Yahoo Finance • 2 months ago

Is Alnylam Pharmaceuticals (ALNY) The Best Growth Stock?

​Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the Best Growth Stocks to Buy With Highest Upside Potential. Wall Street has a positive view on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) as 71% of the 28 analysts covering the stock... Full story

Yahoo Finance • 2 months ago

Alnylam Pharmaceuticals (ALNY) Achieved Free Cash Flow Breakeven in 2025

ClearBridge Investments, a global equity manager, recently published first-quarter 2026 commentary for its “Large Cap Growth Strategy”. A copy of the letter can be downloaded here. Following the outbreak of the Middle East conflict, the ma... Full story

Yahoo Finance • 2 months ago

BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer

BioCryst Pharmaceuticals, Inc. — Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval — RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceu... Full story

Yahoo Finance • 2 months ago

Notable healthcare headlines for the week: Apellis, Centessa, and UnitedHealth in focus

Wall Street’s major market averages ended mixed on Thursday as markets assessed President Donald Trump’s address to the nation and the latest developments in the Middle East conflict. The tech-focused Nasdaq Composite finished +0.1%. At t... Full story

Yahoo Finance • 2 months ago

5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up

Quick Read Incyte (INCY) posted FY2025 revenue of $5.14B (+21.2% YoY) with 14 pivotal trials underway across KRASG12D and CDK2 inhibition, while Alnylam (ALNY) achieved first full-year GAAP profitability with FY2025 revenue surging 65.2%... Full story

Yahoo Finance • 2 months ago

Why Alnylam Pharmaceuticals Inc. (ALNY) is One of the Best High Growth Healthcare Stocks to Buy Now

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is one of the best high growth healthcare stocks to buy now. Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) announced on March 24 a set of strategic efforts aimed at accelerating earlier recognition a... Full story

Yahoo Finance • 2 months ago

Stock Market Today, March 26: Wave Life Sciences Plunges After High Dose Obesity Drug Data Disappoints

Wave Life Sciences(NASDAQ:WVE), developer of RNA medicines for rare genetic diseases, closed Thursday at $6.20, down 49.59% for the session. The stock sank after disappointing higher-dose WVE-007 obesity data underperformed the lower dose.... Full story

Yahoo Finance • 2 months ago

Alnylam (ALNY) Targets 25% CAGR with Innovative Therapies

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) ranks among the best rebound stocks to buy right now. On March 2, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) outlined its growth strategy at the TD Cowen 46th Annual Health Care Conference, emph... Full story